Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family

S Akahani, P Nangia-Makker, H Inohara, HRC Kim… - Cancer research, 1997 - AACR
S Akahani, P Nangia-Makker, H Inohara, HRC Kim, A Raz
Cancer research, 1997AACR
Abstract Galectin-3, a β-galactoside-binding protein, has been shown to be involved in
tumor progression and metastasis. Here, we demonstrate that expression of galectin-3 in
human breast carcinoma BT549 cells inhibits cis-diamminedichloroplatinum (cisplatin)-
induced poly (ADP-ribose) polymerase degradation and apoptosis, without altering Bcl-2,
Bcl-XL, or Bax expressions. Galectin-3 contains the NWGR amino acid sequence highly
conserved in the BH1 domain of the bcl-2 gene family, and a substitution of glycine to …
Abstract
Galectin-3, a β-galactoside-binding protein, has been shown to be involved in tumor progression and metastasis. Here, we demonstrate that expression of galectin-3 in human breast carcinoma BT549 cells inhibits cis-diamminedichloroplatinum (cisplatin)-induced poly(ADP-ribose) polymerase degradation and apoptosis, without altering Bcl-2, Bcl-XL, or Bax expressions. Galectin-3 contains the NWGR amino acid sequence highly conserved in the BH1 domain of the bcl-2 gene family, and a substitution of glycine to alanine in this motif abrogated its antiapoptotic activity. Our findings demonstrate that galectin-3 inhibits apoptosis through a cysteine protease pathway and highlight the functional significance of the NWGR motif in apoptosis resistance of a non-Bcl-2 protein.
AACR